©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Chromosomal Localization and Catalytic Properties of the Recombinant Subunit of Human Lymphocyte Methionine Adenosyltransferase (*)

(Received for publication, March 22, 1995; and in revised form, June 26, 1995)

James De La Rosa (1)(§) Jacek Ostrowski (1)(¶) Monika M. Hryniewicz (1)(**) Nicholas M. Kredich (1) Malak Kotb (2) (3) (6)(§§) H. Leighton LeGros , Jr. (2) (3) Marc Valentine (5) Arthur M. Geller (4)

From the  (1)Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710 Departments of (2)Surgery (3)Microbiology and Immunology (4)Biochemistry, University of Tennessee, Memphis, Tennessee 38163, (5)St. Jude Children's Research Hospital, Memphis, Tennessee 38101 (6)Veterans Administration Medical Center, Research Service, Memphis, Tennessee 38104

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Human lymphocyte methionine adenosyltransferase (HuLy MAT) consists of heterologous subunits alpha and beta. The cDNA sequence of the alpha subunit of HuLy MAT from Jurkat leukemic T cells was identical to that of the human kidney alpha subunit and highly homologous to the sequence of the extrahepatic MAT from other sources. The 3`-untranslated sequence was found to be highly conserved, suggesting that it may be important in regulating the expression of MAT. The extrahepatic alpha subunit of MAT was found to be expressed also in human liver, and no differences were found in the sequence of the alpha subunit from normal and malignant T cells. The sequence of two unspliced introns found in the cDNA clones from the Jurkat library enabled us to isolate genomic clones harboring the human extrahepatic alpha subunit gene and to localize it to the centromere on chromosome arm 2p, an area that corresponds to band 2p11.2.

Expression of the alpha subunit cDNA in Escherichia coli yielded two peptides with the immunoreactivity and mobilities of authentic alpha/alpha` subunits from HuLy. The K of the recombinant alpha subunit was 80 µM, which is 20-fold higher than found for the (alphaalpha`)(x) beta(y) holoenzyme purified from leukemic lymphocytes and 4-10-fold higher than found for the normal lymphocyte enzyme. The data suggest that the alpha/alpha` subunits mediate the enzyme catalytic activity and that the beta subunit may be a regulatory subunit of extrahepatic MAT.


INTRODUCTION

Methionine adenosyltransferase (MAT; (^1)S-adenosyl-L-methionine (AdoMet) synthetase, EC 2.5.1.6) catalyzes the formation of AdoMet from ATP and L-methionine(1, 2) . In mammals, two major MAT isozymes have been described which differ with respect to tissue distribution and kinetic properties (for review see (3) ). Liver contains an isozyme unique to this organ, which has a high K for L-methionine (S(0.5) of 0.2-0.5 mM) and is relatively insensitive to product inhibition by AdoMet(4, 5) . This isozyme has been studied most extensively in the rat, where it has been previously designated the high K form (6, 7) or the beta isozyme (8) but is now called MAT III(4) . The rat liver MAT III isozyme has been purified to homogeneity and was found to exist as a homodimer of a single hepatic alpha subunit (alpha(h)) with a predicted mass of 43.7 kDa but which migrates on polyacrylamide gel electrophoresis in sodium dodecyl sulfate (SDS-PAGE) as a 48-kDa protein(4, 9, 10, 41) . The tetrameric form of this same subunit (alpha(h))(4), which is known as MAT I, has an ``intermediate'' K for L-methionine (about 17-23 µM) (4, 5, 6, 11) and can be converted to the dimeric form by treatment with lithium bromide(10) . Rat MAT I and MAT III can be separated easily by hydrophobic chromatography on phenyl-Sepharose columns(4) . Although human liver expresses the mRNA that encodes the alpha(h) subunit(12, 13) , which is highly homologous to the rat alpha(h) subunit(14) , the existence of a MAT I and MAT III equivalent in human liver has yet to be determined. The rat and human liver-specific alpha(h) subunits are not expressed in extrahepatic tissues.

Extrahepatic tissues contain MAT isozymes that are very different from that of liver and are characterized by low K values for L-methionine (3-20 µM) and by their strong feedback inhibition by AdoMet(15, 16) . Such isozymes have been partially purified from rat kidney(4, 8) , rat lens(17) , and human erythrocytes (15, 18) and completely purified from human lymphocytes (19) and bovine brain(20) . The human lymphocyte isozyme is strongly inhibited by AdoMet(15, 16, 19) . The low K isozyme is expressed in all tissues including the liver(4, 7, 21) . However, recent studies suggest that different tissues, or even cells from the same tissue at different stages of development, can express different forms of the extrahepatic enzyme(3, 4, 7, 21) . In contrast to the rat liver isozymes that represent different polymeric states of the alpha(h) subunit (41) , the purified enzyme from human leukemic lymphocytes and from bovine brain consists of heterologous subunits, known as alpha (53 kDa) and beta (38 kDa)(19, 20, 21, 22) . In human T cells the alpha subunit appears to undergo some type of post-translational modification to yield a 51-kDa protein called alpha`(19) . MAT from leukemic T cells has a native molecular weight of 185,000 (19) and thus may have a possible subunit structure of alphaalpha`beta(2), but since the molar ratio of each subunit in the holoenzyme is not known, we will refer to this form as (alphaalpha`)(x) beta(y). In resting human T cells and stage M(3) acute myelogenous leukemia cells, MAT activity is primarily associated with a 68-kDa protein called , which is immunocross-reactive with the (alphaalpha`)(x) beta(y) form of MAT(21) . The subunit can exist alone or in association with alpha/alpha` and/or beta(21) . The beta subunit is unrelated to alpha/alpha` with respect to peptide maps and immunoreactivity(19, 23) .

The cDNA of MAT alpha subunit from human kidney has been cloned and sequenced and was found to be 99% homologous to the rat kidney MAT alpha subunit protein(24) . The kidney alpha subunit and the liver alpha(h) subunit are clearly different; however, at the protein level they are 85% identical. Inasmuch as studies of the MAT protein expression in the kidney showed no expression of the beta subunit that is expressed in lymphocytes and brain tissues, we hypothesized that differences may exist in the sequence of the alpha subunit of MAT from different tissues and that these differences may affect the association between the alpha and the beta subunits of extrahepatic MAT. The present study was undertaken to determine whether differences exist between: (i) MAT alpha subunit from different human extrahepatic tissues, namely kidney versus lymphocytes; and (ii) MAT alpha subunit from normal and malignant tissues. We report that the sequence of the MAT alpha subunit from human kidney and normal or malignant lymphocytes is identical and that the gene for the alpha subunit of MAT is located on chromosome 2p11.2. We report also the expression of the alpha subunit in Escherichia coli and demonstrate that, although it is catalytically active in the absence of beta subunit, its kinetics are different from the native (alphaalpha`)(x) beta(y) form of MAT found in normal and malignant lymphocytes.


EXPERIMENTAL PROCEDURES

Strains and Media

The E. coli strains used were: NM522, which is supE thi Dhsd5 (r,m)D[lac- proAB][F`proAB lacI-ZDM15]; Y1090, which is D(lac)U169 D(lon) hsdR araD139 strA supF mcrA trpC22::Tn10(pMC9); and strain XL-1 Blue (Stratagene), which is endA1 supE44 hsdR17 (r,m)thi lrecA1 gyrA96 lac [F`proAB lacIZDM15 Tn10 (tet)]. phage derivatives were plated in top agar consisting of NZYCM (25) containing 0.7% agarose. Plasmid strains were grown on LB or 2 times YT (25) containing 50-100 µg/ml ampicillin. pDR540 contains the tac promoter (26) and was purchased from Pharmacia Biotech Inc.

Peptide Sequences from MAT

Human lymphocyte MAT was purified from leukemic lymphocytes as described by Kotb and Kredich (19) except that all steps were done at room temperature, and anion exchange chromatography and gel filtration chromatography were performed with Mono Q HR 10/10 and Superose-12 HR 10/30 columns (Pharmacia). Resolution of the alpha/alpha` and beta subunits of MAT and of tryptic peptides was achieved by HPLC. A lyophilized sample of purified MAT was dissolved in 70% formic acid and applied to a Vydac C4 peptide/protein column (4.6 mm times 25 cm; particle size, 5 mm; pore size, 330 Å; Rainin Instrument Co.), which was equilibrated with 0.1% (w/v) trifluoroacetic acid and 10% HPLC grade acetonitrile (v/v) at a flow rate of 1 ml min. After 10 min of isocratic perfusion, the acetonitrile concentration was increased at a linear rate of 1% min. The eluate was monitored at 214 and 280 nm, and semiquantitative estimates of peaks were made from integrated values of absorbance at 214 nm and a neurotensin standard. Neurotensin was eluted from the column at 27 min. Using SDS-PAGE(27) , we identified a single peak containing both alpha and alpha` subunits, which was eluted at 42.1 min, and another peak containing the beta subunit, which was eluted at 44.4 min. When holoenzyme was dissolved in 0.1% trifluoroacetic acid rather than in 70% formic acid, a single peak appeared at 42.8 min, which contained all three subunits. A 260-µg portion of purified alpha/alpha` subunit was lyophilized to dryness and dissolved in 1 ml of 1% ammonium bicarbonate. Trypsin was added to a final concentration of 10 µg/ml; after incubation for 4 h at 37 °C, the solution was lyophilized to dryness and dissolved in a small volume of 70% formic acid. This material was then applied to the Vydac C4 column, which was equilibrated with 0.1% (w/v) trifluoroacetic acid and 10% acetonitrile (v/v), at a flow rate of 1 ml min. After 10 min of isocratic perfusion, the acetonitrile concentration was increased at a rate of 1% min for the next 14 min and then at a rate of 0.25% min for the next 36 min. The eluate was monitored at 214 and 280 nm, and fractions of interest were lyophilized to dryness and analyzed by gas phase peptide sequencing(28) .

General Nucleic Acid Methods

RNA was prepared from cultured lymphocytes by cell lysis with guanidine thiocyanate (29) followed by centrifugation over a cushion of cesium-trifluoroacetate (r = 1.522 g/ml) at 15 °C for 20 h at 125,000 times g. Poly(A) RNA was purified from total RNA on an oligo(dT)-cellulose column from Pharmacia. Oligodeoxynucleotides were prepared with an Applied Biosystems model 380A automated DNA synthesizer and 5`-labeled with ATP (3,000 Ci/mmol) and T4 polynucleotide kinase(30) . Double-stranded DNA was labeled with [alpha-P]dCTP (3,000 Ci/mmol) by the random primer method (31) to specific activities of 1-2 times 10^9 cpm/µg. DNA sequencing was performed by the method of Sanger et al.(32) with specific oligodeoxynucleotide primers and single-stranded templates derived with helper phage from pT7T3 derivatives in NM522 (33) or from pBluescript SK derivatives in strain XL-1 Blue (Stratagene). Templates were sequenced either with a primer designed for use with these phagemids or with synthetic oligodeoxynucleotides corresponding to previously determined sequences.

cDNA Libraries

An adult human liver cDNA library (34) in gt11 was obtained from Jack Keene, and a Jurkat human T cell cDNA library in ZAP was generated by Dr. M. Kotb (Memphis) and Dr. M. Snead from Stratagene. Both libraries were derived from oligo(dT)-primed poly(A) RNA. A random-primed cDNA library was prepared from Jurkat T cell poly(A) RNA (provided by Warner Greene) with a You-Prime cDNA synthesis kit (Pharmacia) and random hexamers. After the addition of EcoRI/NotI adapters, the cDNA was ligated into the dephosphorylated arms of EcoRI-digested ZAP (Stratagene). This product was then packaged into phage particles and plated on the E. coli strain XL-1 Blue. The same procedure was used to construct a specific-primed cDNA library from Jurkat T cell poly(A) RNA and oligo, a 26-mer oligodeoxynucleotide (5`-TCAGGATCCTGCTGAAGGTGGGCATC-3`) corresponding to the coding strand from positions 152 to 127. Approximately 3.5 times 10^5 plaques were obtained for the random-primed library and 26,000 for the specific-primed library. The insert frequency for both was greater than 90% as judged by ratios of white to blue plaques on medium containing isopropyl-beta-D-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside.

Screening of cDNA Libraries

Phage were plated on either Y1090 for the gt11 library or on XL-1 Blue for the ZAP libraries at 3-5 times 10^4 plaque-forming units/150-cm^2 Petri dish. After 8-12 h at 37 °C, plaques were transferred and bound to nitrocellulose filters as described previously(25) . For screening with DNA probes, filters were prehybridized for 2-5 h at 42 °C in 6 times NET (0.15 M NaCl, 1 mM EDTA, 15 mM Tris-HCl, pH 8.3), 1 times Denhardt's solution, 0.1% SDS, containing 200 µg/ml nicked and denatured salmon sperm DNA and 20-50% formamide. Hybridization was performed for 12-16 h at 42 °C in the same solution containing probe at 10^6 cpm/ml and lacking the salmon sperm DNA. Filters were washed three times for 20 min each at 23 °C in 2 times NET, 0.1% SDS and then once for 60 min at 53 °C in 0.2 times NET, 0.1% SDS. Positive plaques were identified by radioautography.

For the random-primed and specific-primed libraries, filters were prehybridized for 3-5 h at 42 °C in 6 times NET, 4 times Denhardt's solution, 0.05% pyrophosphate, 0.1% SDS, and 200 µg/ml nicked and denatured salmon sperm DNA. Filters were hybridized overnight at 42 °C in the same solution minus salmon sperm DNA with a probe consisting of a P-labeled 36-mer oligodeoxynucleotide (oligo see below), which was complementary to a previously determined cDNA sequence. Following hybridization, filters were washed three times for 20 min each with 6 times NET, 0.1% SDS at 23 °C and then twice for 5-10 min each at 45 °C in 2 times NET, 0.1% SDS. Plaques giving positive signals were purified by replating. phage DNA was prepared by the method of Chisholm(35) , and EcoRI inserts were subcloned in pT7T3 19U for DNA sequencing. pBluescript SK phagemids were obtained from ZAP derivatives by in vivo excision with helper phage as recommended by Stratagene.

Cloning and Sequencing of MAT alpha Subunit cDNA from Normal Human Lymphocytes

Normal, resting T cells (2 times 10^8) were incubated at 37 °C in 5% CO(2) and 95% humidity, stimulated with phytohemagglutinin A (PHA) (5 µg/ml), and harvested 48 h later. RNA was extracted from the T cell-enriched populations using RNAzol-B (TEL-TEST INC., Friendswood, TX). First-strand cDNA was prepared from total RNA using superscript reverse transcriptase (Life Technologies, Inc.) and random hexanucleotides (Boehringer Mannheim). The reaction contained, per 20 µl: 2 µl of 10 times PCR buffer (0.2 M Tris-HCl, pH 8.4, 0.5 M KCl, 15 mM MgCl(2), and 100 µg/ml nuclease-free bovine serum albumin); 2 µl of 10 mM dNTPs mix; 2 µg of random hexanucleotides; 2.5 mM dithiothreitol; 1 unit of RNase inhibitor; and 200 units of reverse transcriptase/µg of RNA. The reaction was incubated for 45 min at 37 °C and terminated by heating at 95 °C for 10 min followed by rapid chilling in ice water for 2 min. The alpha subunit cDNA was amplified in the presence of Taq polymerase (0.25 unit) using the following primers. For MAT alpha subunit the forward primer was 5`-GCC-GCT-GCT-CCT-TCG-TAAG-3`, and the reverse primer was 5`-TAA-CCT-ACG-CCA-ACA-AGT-CT-3`; together they amplified a 1273-bp product. These PCR primers covered the entire ORF of the alpha subunit cDNA. The amplified PCR product was purified and sequenced either directly by cycle sequencing using the fmol sequencing kit (Promega) or cloned into the TA cloning vector (pCR II Vector, Invitrogen Corp., San Diego) and subcloned into competent E. coli strain INValphaF` competent cells for sequencing of positive plasmids by the dideoxy termination method using the Sequenase II kit (Upstate Biotechnology, Inc.). The sequences were compared and aligned to previously derived MAT gene sequences using GenBank.

Genomic Cloning and Chromosomal Localization of Human MAT alpha Subunit Gene

PCR primers were chosen to amplify genomic DNA from position 102 of intron B, which was found in the Jurkat library, to position 824 of the coding sequence. The sequence of the forward primer was 5`-GGA-GGA-TAT-TTG-CTG-AAT-GA-3`, and that of the reverse primer was 5`-ACC-CCA-ACC-GCC-ATA-AGT-GT-3`; together these primers amplified a 147-bp product. The primers were used to screen a human P1 genomic library (Genome Systems Inc. St. Louis, MO). The library consisted of 50,000 clones arranged in 26 pools of 2,000 clones each. The positive clones were sequenced to ensure that they harbored the alpha subunit gene. Highly purified DNA from one of the positive clones was used to probe human chromosomes for the alpha subunit gene. Purified DNA from P1 clone 2007 was labeled with digoxigenin dUTP by nick translation. Labeled probe was combined with sheared human DNA and hybridized to normal metaphase chromosomes derived from PHA-stimulated peripheral blood lymphocytes in a solution containing 50% formamide, 10% dextran sulfate, and 2 times SSC. Specific hybridization signals were detected by incubating the hybridized slides in fluorescein-conjugated antidigoxigenin antibodies. The chromosomes were counterstained with propidium iodide and analyzed.

Other Methods

Bacterial cell extracts were prepared by suspending cell paste in 2-4 volumes of ice-cold 0.1 M Tris-HCl, pH 7.6, and disrupting them by sonification. Cellular debris was removed by centrifugation for 30 min at 20,000 times g, and supernatants were stored at -70 °C. MAT activity was determined as described previously (19) with varying concentrations of L-[^14C]methionine. One unit of MAT activity is defined as the amount of enzyme that catalyzes the formation of 1 nmol of AdoMet/h. Protein was determined by the dye-ligand method (36) with bovine serum albumin as a standard. Immunoblots of proteins that had been separated in a 10% SDS-PAGE gel were prepared as described previously(36) . The first antibody consisted of a polyclonal rabbit antiserum against highly purified human lymphocyte MAT(36) . Nonspecific binding of rabbit immunoglobulin to E. coli proteins was prevented by diluting the antiserum 500-fold in a buffer containing 1 mg/ml protein from a crude extract of NM522. The second antibody was horseradish peroxidase-conjugated, affinity-purified goat antiserum to rabbit immunoglobulin G (Bio-Rad). Color development was accomplished with hydrogen peroxide and 4-chloro-1-naphthol as the chromophore.


RESULTS

Peptide Sequences

Attempts to obtain an amino acid sequence for the intact alpha/alpha` subunit preparation were unsuccessful, indicating that the amino terminus is blocked. Amino acid sequences were obtained for five tryptic peptides containing a total of 46 different residues (Fig. 1).


Figure 1: Nucleotide sequences of cloned DNA. Panel A shows the cDNA for the alpha/alpha` subunit of human lymphocyte MAT. The sequence was determined from clones isolated from three different Jurkat T cell libraries. The deduced amino acid sequence is shown for the ORF. Nucleotides are numbered beginning at the first position of the ORF. Amino acid positions are shown in parentheses. The positions of putative introns A and B are shown as well as the HindIII site and a polyadenylation signal. Shaded amino acid residues correspond to tryptic peptide sequences that were chemically determined from purified alpha/alpha` subunit. Panel B shows the sequence of partial intron A, which consists of 245 bp upstream of position 45 in isolate HLy29.1, and the sequence of the 191-bp intron B, which is complete and was found between positions 768 and 769 in isolate HLy45.1.



Comparison of the Extrahepatic alpha Subunit cDNA Sequence from Different Human Tissues

To determine whether different human tissues express the same alpha subunit of MAT, we sequenced the alpha subunit from leukemic T cells. For this purpose, an oligo(dT)-primed Jurkat T cell cDNA library in ZAP was generated. To screen this library, we first screened an adult human liver library in gt11 with a 1.3-kb probe consisting of the entire coding region of rat liver MAT (14) plus 74 bp of 5`-untranslated sequence and 58 bp of 3`-untranslated sequence. Of a total of 2 times 10^5 plaques screened, only two positive clones were identified, designated XHM4.1 and XHM4.2, with inserts of 1.25 and 1.35 kb, respectively. The sequences of these isolates overlapped and covered a total length of approximately 1.4 kb (see below) and contained an ORF of 118 codons, which was virtually identical to that of human kidney(24) . It was therefore appropriate to use these probes for screening the Jurkat library. A 0.35-bp EcoRI/HindIII fragment that contained almost the entire ORF from isolate XHM4.1 was used to probe the Jurkat library. From approximately 5 times 10^5 plaques, eight clones were isolated and characterized. The overlapping inserts provided a 2,649-bp sequence extending from position 45 to position 2693 relative to what was eventually determined to be the start codon of the ORF of the lymphocyte enzyme (Fig. 1) and the human kidney enzyme(24) . Isolate HLy31.1 was completely sequenced on both strands and extended from position 47 to 1478. Isolate HLy36.3 was sequenced for 85% of its length on the coding strand (all but positions 1978-2299) and for 82% of the noncoding strand (all but positions 851-1120 and 2621-2620). Other isolates are shown in Fig. 2and were sequenced for approximately 300 bp on one or both ends to establish their position in the overall sequence. Isolate HLy29.1 extended from position 45 to 1032 and contained an additional 235 bp of upstream noncoding sequence. The junction between this segment and nucleotide 45 is AG/GG, which is characteristic for the 3` end of an unspliced intron, which we have designated intron A ( Fig. 1and Fig. 2). Further screening of the oligo(dT)-primed Jurkat library failed to identify a clone containing sequence upstream to position 45. Therefore, we constructed additional specific- as well as random-primed libraries and probed them with a 36-mer oligodeoxynucleotide (oligo, 5`-TATCGGATCCTCACAAATCTTATCTGGGTGGC CTTC-3`), which consists of a 3` end of 26 nucleotides complementary to a previously obtained sequence between positions 79 to 104 (Fig. 1), preceded by 10 nucleotides, which are not complementary to the sequence and contain a BamHI site. A single positive clone, designated HLy49.1, was obtained from the specific-primed library and gave upstream sequence to -82 (Fig. 1).


Figure 2: Orientation of cloned cDNA segments from the human lymphocyte and human liver phage libraries. The nine clones from the lymphocyte libraries are shown at the top, and the two clones from the liver library, XHM4.1 and XHM4.2, are shown at the bottom of the figure. A 245-bp putative partial intron (intron A) is shown at the upstream boundary of isolate HLy29.1. A 191-bp complete putative intron (intron B) is shown within the sequence of isolate HLy45.1. The scale begins at position 1 of the ORF &cjs2110;. The cDNA spans a total of 2,693 bp, not including the poly(A) region. The ends of all phage inserts contain EcoRI sites (not shown), which were introduced during library construction. The only internal EcoRI site was found in intron B.



Ten clones were obtained from the random-primed library, and one of these, designated HLy45.1, was characterized in detail. It contained the sequence between positions -94 and +847 but was also found to have an additional 191 bp between positions +768 and +769. The sequences at the 5` and 3` junctions of this segment, CAG/GT and AG/GG, are characteristic for an unspliced intron, which we have designated intron B ( Fig. 1and Fig. 2). The single EcoRI site in this putative intron is unlikely to be a cloning artifact because it does contain the adjacent NotI site present in the adapter used for cloning. The final cDNA sequence of 2,787 bp contains a 395-codon ORF encoding a 43.6-kDa polypeptide in which all five of our chemically determined tryptic peptide sequences are present (Fig. 1). The putative start codon at position +1 is found within the sequence CAACATGA, which is identical to the -4 to +4 consensus initiator sequence C(A/G)CCATGG (37) at 6 of 8 positions. The Met-Asn sequence that begins this ORF would be expected to be acetylated in eukaryotes to give N-acetyl-Met-Asn(38) , which would explain our finding of a blocked amino terminus for the purified alpha/alpha` peptide. The sequence of the HuLy MAT was identical to that of human kidney MAT(24) . However, the Jurkat library provided additional 3`-untranslated sequence totaling 1,505 bp, not including the poly(A) tail and including the polyadenylation signal sequence AATAAA (39, 40) beginning 23 bp upstream of the poly(A) region.

No sequence differences were noted in the various isolates obtained from the three Jurkat T cell libraries. The two clones obtained from the adult human liver library corresponded to positions 830-2068 (XHM4.1) and positions 854-2236 (XHM4.2) and were sequenced for about 500 bp from both ends. The sequence of the XHM4.1 and the XHM4.2 fragments was identical to the alpha subunit cDNA sequence from Jurkat cells. An A and a T located at positions 837 and 846 of human lymphocyte and kidney cDNA were replaced by a G and a C in the XHM4.1 and XHM4.2 fragments from human liver. This is most likely a cloning artifact related to a 5-methyl cytosine spontaneous mutation in E. coli strains that are able to perform the methylation reaction. In these strains the mutation creates a GC to AT transition. However, these base substitutions, which occurred in the third positions of codons 278 and 281, gave synonymous codons for glycine and phenylalanine, respectively. XHM4.1 contained a C at position 2222 in the 3`-untranslated region in place of the T found in human lymphocyte cDNA. These data show that the extrahepatic alpha subunit of MAT is also expressed in human liver.

Comparison of the alpha Subunit cDNA Sequence in Normal and Malignant Human Lymphocytes

To determine whether sequence differences exist between MAT alpha subunit in normal and malignant tissues, the alpha subunit cDNA from normal human T cells was also sequenced. Primers that bracket different regions of the ORF and including positions -44 to +1229 were used to amplify cDNA from normal T cells that have been activated for 48 h with PHA. In resting T lymphocytes MAT activity is predominately associated with (p68), which is replaced by the alpha/alpha` subunit when T cells are activated. Activation with PHA was, therefore, necessary to induce alpha subunit mRNA expression, which is normally expressed at very low level in resting T cells. (^2)The amplified PCR product was either directly sequenced or subcloned into a TA cloning vector and then sequenced. Sequencing covered positions -44 to 280, 507-780, 780-840, 841-1229. These sequences were identical to the sequence of the alpha subunit cDNA from the leukemic T cells (data not shown).

Genomic Cloning and Chromosomal Localization of the Human Extrahepatic alpha Subunit of MAT

Purified DNA from P1 clone 2007 was labeled with digoxigenin dUTP and hybridized to normal metaphase chromosomes derived from PHA-stimulated peripheral blood lymphocytes. Specific hybridization signals were detected using fluorescein-conjugated antidigoxigenin antibodies and counterstaining with propidium iodide. Hybridization with clone 2007, which contains the extrahepatic alpha subunit gene, resulted in the specific labeling of the proximal short arm of a group A chromosome the size and morphology of which were consistent with chromosome 2. A second experiment was conducted in which a chromosome 2 centromere-specific probe (D2Z1) that was biotinylated was labeled with biotin dUTP and cohybridized with the P1 clone. Specific hybridization signals were detected using fluorescein-conjugated antidigoxigenin and Texas red avidin followed by counterstaining with DAPI. The data shown in Fig. 3clearly demonstrate that clone 2007 is located immediately distal to the centromere on chromosome arm 2p, an area that corresponds to band 2p11.2.


Figure 3: Chromosomal localization of the human alpha subunit of MAT. Hybridization was done using P1 clone 2007 that harbors the alpha subunit gene. The gene was localized to chromosome arm 2p, an area that corresponds to band 2p11.2. Chromosome 2 centromere-specific probe (D2Z1) was labeled with biotin dUTP and cohybridized with the P1 clone labeled with digoxigenin dUTP. Specific hybridization signals were detected using fluorescein-conjugated antidigoxigenin and Texas red avidin followed by counterstaining with 4,6-diamidino2-phenylindole.



Expression of alpha/alpha` Subunit cDNA in E. coli

Digestion of pDR540 with HindIII and BamHI gave a 91-bp fragment containing the tac promoter and a Shine-Dalgarno sequence(42) , which was situated just upstream of the BamHI site. pKMN1 was constructed by ligation of this fragment into the polylinker region of pT7T3 19U. A 1.34-kb BamHI/EcoRI fragment, which contained all but the amino-terminal 143 bp of the human lymphocyte MAT alpha/alpha` subunit coding region (Fig. 4), was then purified from HLy31.1 and ligated into pKMN1 to give pMAT351. A fragment containing the missing amino-terminal portion of the coding region was synthesized by PCR with template DNA from HLy45.1 and an upstream primer, 5`-GGAATTCGGATCCTATGAACGGACAGCTCAACGG-3`, which consists of 13 nucleotides at the 5` end containing a BamHI site followed by a T and then 20 nucleotides corresponding to the noncoding strand at positions 1-20. The downstream primer, oligo, was identical with the coding strand from position 152-127. Following digestion of the PCR product with BamHI, the 148-bp fragment was purified by PAGE and inserted into the BamHI site of pT7T3 18U. Several isolates were sequenced to verify the absence of PCR-generated mistakes. The BamHI fragment from one such isolate was then inserted into pMAT351; following transformation into NM522, a recombinant plasmid containing a complete ORF oriented downstream of the tac promoter was identified by DNA sequencing and designated pMAT355 (Fig. 4). The same methods were used to construct pMAT356, which is identical to pMAT355 except that the starting vector was pT7T3 18U.


Figure 4: Construction of expression vector pMAT355. A regulatory region containing the tac promoter with downstream Shine-Dalgarno sequences (SD) (42) was derived from pDR540 as a HindIII/BamHI fragment and inserted into pT7T3 19U. Isolate HLy31.1 provided a 1.3-kb fragment containing the coding region for the alpha/alpha` subunit of human lymphocyte MAT extending from position 145 (relative to the translation start site) to a position 282 bp downstream of the translation terminator. The first 144 bp of the ORF were obtained by PCR with template from isolate HLy45.1 and contained an upstream BamHI site suitable for ligation immediately downstream of the regulatory region. The lower portion of the figure shows the sequence of the regulatory region containing the tac promoter (-35 and -10 regions) with Shine-Dalgarno sequences followed by the first three codons of the ORF for the alpha subunit.



The lacI^q strain NM522, containing either pMAT355 or pMAT356, was grown on 2 times YT medium to a density of about 4 times 10^8 cells/ml, and IPTG was added at 0.5 mM. Control cultures were treated in the same way but did not receive IPTG. After an additional 2.5 h of growth, cells were harvested, and the expression of the alpha subunit was examined. Immunoblots of an SDS-PAGE gel probed with a polyclonal antibody to highly purified human lymphocyte MAT holoenzyme (23) showed two bands in extracts from IPTG-induced NM522 (pMAT355), which migrated almost identically with the 53-kDa alpha band and the 51-kDa alpha` band of the human lymphocyte MAT holoenzyme (Fig. 5). These two bands were not present in the extract from uninduced NM522 (pMAT355). By comparison with standards and by assuming equivalent immunoreactivity, we estimated that the alpha subunit protein accounted for approximately 6% of the total protein in induced NM522 (pMAT355). No band corresponding to the 38-kDa beta subunit was noted in bacterial extracts.


Figure 5: An immunoblot of the human lymphocyte MAT alpha/alpha` subunit expressed in E. coli. Portions of crude extracts from NM522 (pMAT355) that had been grown with and without the inducer IPTG were analyzed by SDS-PAGE together with a human lymphocyte MAT alpha/alpha` standard, and immunoblots were prepared with polyclonal rabbit antiserum against the highly purified lymphocyte enzyme(23) . The quantities shown represent the amounts of total protein applied to the gel from either the crude extracts or a preparation of human lymphocyte MAT that was approximately 90% pure. The positions of the alpha, alpha`, and beta subunits of the human lymphocyte enzyme are indicated and migrate with apparent molecular masses of 53, 51, and 38 kDa. No bands were noted with the extract from uninduced NM522 (pMAT355). The beta subunit band was not detected in the E. coli extracts.



Catalytic and Kinetic Properties of Recombinant alpha Subunit

The alpha subunit appears to have enzymatic activity because AdoMet catalytic activity was found to be approximately 20-fold greater in a crude extract from induced NM522 (pMAT355) than in NM522 (no plasmid) and 1.5-fold higher in an extract from uninduced NM522 (pMAT355). Catalytic activities in extracts from induced and uninduced cultures of the control strain NM522 (pT7T3 19U) were no higher than in NM522 (no plasmid). These assays were performed at 5 mM ATP and 100 µML-methionine. Measurements of the K(m) for L-methionine were carried out at 5 mM ATP with L-methionine concentrations varying from 5 to 500 µM. At low L-methionine concentrations the K(m) value was 60 and 80 µM for NM522 and induced NM522 (pMAT355) extracts, respectively. At high L-methionine concentrations K(m) values were 80 and 200 µM, respectively.


DISCUSSION

The existence of multiple isozymes of MAT in mammalian tissues is well established (for review see (3) and (43) ). Whereas the liver-specific enzyme appears to be a homodimer or tetramer of a single alpha(h) subunit(41) , the extrahepatic enzyme that is expressed in all tissues appears to consist of nonidentical alpha and beta subunits. Several complementary pieces of evidence indicate that the cDNA we have characterized from Jurkat T cell libraries is that of the alpha subunit of human lymphocyte MAT. First, the deduced amino acid sequence is identical to that of the alpha subunit from human kidney (24) and highly homologous to that of other MATs (see below). Second, the sequence contains the five tryptic peptide sequences that were chemically determined from purified, native alpha/alpha` subunit. Third, expression of this cDNA in E. coli gave two peptide bands that comigrated with authentic alpha and alpha` subunits in SDS-PAGE and reacted with antiserum to human lymphocyte MAT. The fact that the alpha subunits of MAT in human lymphocytes, kidney, and liver are identical suggests that the sequence of this subunit is the same in all tissues.

Several studies have reported that MAT activity is elevated in malignant cells(6, 22, 44, 45, 46) . Furthermore, Liau et al.(6, 7, 47, 48) demonstrated the presence of an altered form of MAT in tumors. In this study we show that the sequence of the alpha subunit is the same in normal and malignant lymphocytes. These findings do not rule out the possibility that the expressed protein may be altered post-translationally in malignant lymphocytes. However, immunoblot analysis of cell extracts shows a very similar pattern for leukemic and normal activated T lymphocytes(21, 22) . Additional studies are needed to determine whether differences exist in the regulation and expression of MAT in normal and malignant tissues. These studies may facilitate the development of specific inhibitors that specifically block MAT in malignant tissues(44, 49, 50, 51) .

Comparisons of the deduced amino acid sequence for the human lymphocyte or kidney alpha subunit with those of non-mammalian MAT (not shown) revealed identities of 49% with the E. coli enzyme(52) , 68% with the Aradiposis thaliana enzyme(53) , and 69% with the two yeast enzymes(54, 55) . Identities were found at 84% of positions with the liver alpha(h) subunit from human, rat, and mouse(13, 14, 56) , and at 98.7% of positions with the rat kidney enzyme(57) . This homology at the molecular level confirms previous reports showing that the alpha subunit of human lymphocytes is immunocross-reactive with MAT from E. coli, yeast, and rat liver(23) . Therefore, earlier reports by Abe et al.(9) , which failed to detect cross-reactivity between the hepatic and the kidney enzymes in rat, may represent differences in the amount of proteins or the antibodies used in the immunologic studies.

Earlier studies by Horikawa et al.(57) suggested that the rat kidney alpha subunit is not expressed in the liver, but later studies showed that the human kidney alpha subunit is expressed at very low levels in adult liver(12) . However, the data presented here clearly show that the alpha subunit is expressed in human liver because the sequence of the XHM4.1 and XHM4.2 cDNA fragments, which were isolated from an adult human liver library, was identical to that of the extrahepatic alpha subunit. The finding that the extrahepatic alpha subunit is expressed in liver confirms earlier findings by Liau et al. (7) of a human liver isozyme with a low K(m) for L-Met, and a more recent report by De La Rosa et al.(21) in which immunoblots of human liver extracts revealed that adult human liver also expresses the extrahepatic form of MAT.

The deduced amino acid sequences of the human and rat extrahepatic alpha subunit differ at only 5 of 395 positions (Fig. 6). The cDNA sequences for the human lymphocyte alpha subunit and rat kidney enzyme were 93.5% identical. This high degree of identity was even more striking at the 3`-untranslated region, where only a single difference exists (position 39) in the 73 bp downstream of the TGA terminator codons (to position 1260). The 3`-untranslated region was also conserved for the extrahepatic alpha subunit cDNA expressed in adult liver because fragment XHM4.1 contained an identical sequence in this region differing by only 1 base where a C at position 2222 in the 3`-untranslated region was found in place of the T found in human lymphocyte cDNA. Although the sequences of the 3`-untranslated regions of the hepatic alpha(h) subunit and the extrahepatic alpha subunit are quite different, the 3`-untranslated region is highly conserved across different species, suggesting that this region may exert an important regulatory function.


Figure 6: Comparison of the deduced amino acid sequence of the alpha subunit of human lymphocyte MAT with those of the rat liver and rat kidney (57) enzymes. The amino acid sequence shown for the rat liver enzyme is from cDNA that was cloned and sequenced in this laboratory and is identical to that reported by Horikawa et al.(14) except at amino acid position 345, where the Horikawa sequence contains an extra Asp. Residues in the rat sequences that are identical to the human lymphocyte alpha subunit sequence are shaded (&cjs2110;).



The finding of the two introns in the clones derived from the Jurkat library was useful in that it allowed us to select genomic clones that harbor the extrahepatic alpha subunit gene. DNA from these clones enabled us to determine that the gene for the human extrahepatic alpha subunit of MAT is located on chromosome arm 2p, an area that corresponds to band 2p11.2. Recently, the gene for the mouse liver enzyme was localized to chromosome 7(56) . To our knowledge there are no reports of the chromosomal localization of the human liver alpha(h) subunit. Studies that investigate the genomic organization and regulation of MAT isozymes will undoubtedly reveal molecular mechanisms controlling the expression of these enzymes in different mammalian tissues as well as in normal and malignant tissues.

Expression of the alpha subunit in E. coli produced two immunoreactive peptides that are probably equivalent to the alpha and alpha` peptides of HuLy MAT(19, 23) . Total identity would not be expected because of differences in amino-terminal processing, which would give NH(2)-Met-Asn or perhaps NH(2)-Asn in E. coli(58, 59) and N-acetyl-Met-Asn in lymphocytes(38) . Such differences may account for the slightly faster migration of the E. coli-expressed products in SDS-PAGE (Fig. 5). It seems likely, however, that the E. coli products with apparent masses of 53 and 51 kDa are related to each other in the same way that the lymphocyte alpha and alpha` subunits are related. Since mRNA processing and specific post-translational modifications are generally very different between prokaryotes and eukaryotes, we favor a relatively nonspecific process such as proteolysis or deamidation to account for differences between the alpha and alpha` subunits of the lymphocyte enzyme and between their counterparts produced by the E. coli expression strain. Amino acid sequences of the lymphocyte alpha/alpha` subunit that are not present in the rat liver enzyme are possible targets for such a process since the latter gives only a single band in SDS-PAGE. It is of interest in this regard that the deduced alpha/alpha` sequence contains two Asn-Gly dipeptides (at positions 6-7 and 170-171) that are not present in the rat liver enzyme (Fig. 6). The asparaginyl residue in this sequence is known to be particularly susceptible to nonenzymatic succinimide formation with subsequent hydrolysis to an isoaspartyl residue(60, 61) . If the difference between the alpha and alpha` subunits is due to such a modification, one would expect the rat kidney enzyme also to show two bands in SDS-PAGE because its deduced sequence contains the same two Asn-Gly dipeptides. We are unaware of any report on the subunit structure of the rat kidney enzyme.

The 43.6-kDa polypeptide predicted from the ORF of our cDNA is considerably smaller than the values of 53 and 51 kDa estimated by SDS-PAGE for the alpha and alpha` subunits of human lymphocyte MAT(19, 23) . This discrepancy also exists for the HuLy alpha subunit expressed in E. coli and for the rat liver alpha(h) subunit, which has a predicted mass of 43.7 kDa (14) but an estimated mass of about 48 kDa by SDS-PAGE analyses(4, 9, 10, 62) . Anomalously slow migration in SDS-PAGE has been reported for other proteins and in some instances has been attributed to excess charge density (63) or more specifically, to an unusually high content of acidic amino acids(64, 65) . Although the entire deduced alpha/alpha` peptide has a net charge of only -7, many of the basic residues are located in the carboxyl-terminal portion, and the first 240 amino acids have a net charge of -19. A similar asymmetric charge distribution is found in the rat liver enzyme.

The extrahepatic form of MAT has been studied extensively in human lymphocytes(16, 19, 21, 22, 23, 66, 67) , human erythrocytes(15, 18) , rat lens(17, 68) , rat kidney(4) , and bovine brain(20) . The presence of the alpha and beta subunits has been demonstrated in human lymphocytes(19, 21, 22, 23) , human mature erythrocytes(18) , and bovine brain (20) and has been reported to exist in Erlich ascites tumor and calf thymus(20) ; there have been no reports of the existence of the beta subunit in kidney tissues. There is strong evidence to suggest that the alpha subunit is the catalytic subunit, whereas beta may have a regulatory function. Extracts from the E. coli expression strain contained levels of MAT activity which were 20-fold higher than those from E. coli itself. However, a preliminary kinetic analysis of unpurified enzyme indicates that it has a K(m) of 80 µM, which is 20-fold higher than the 4 µM value of MAT from leukemic T cells and 5-fold higher than the 16 µM value for enzyme in crude resting human lymphocytes. Perhaps these findings only reflect differences between lymphocytes and E. coli in amino-terminal processing or some other post-translational modification, but it is intriguing to speculate that the function of the beta subunit may be to impart the kinetic properties that distinguish the lymphocyte enzyme from the hepatic enzyme, i.e. a low K(m) for L-methionine and sensitivity to product inhibition by AdoMet(16, 19) .


FOOTNOTES

*
This work was supported by National Institutes of Health Research Grants DK-12828 (to N. M. K.) and GM-38530 (to M. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) L43509[GenBank].

§
Present address: Pima Community College, Tucson, AZ 85741.

Present address: Bristol-Meyers Squibb Pharmaceutical Research Institute, Buffalo, NY 14213.

**
Permanent address: Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.

§§
To whom correspondence should be addressed: VAMC, Research Service (151), 1030 Jefferson Ave., Memphis, TN 38104.

(^1)
The abbreviations used are: MAT, methionine adenosyltransferase; PAGE, polyacrylamide gel electrophoresis; HPLC, high pressure liquid chromatography; IPTG, isopropyl-beta-D-thiogalactopyranoside; PHA, phytohemagglutinin A; PCR, polymerase chain reaction; bp, base pair(s); kb, kilobase(s); ORF, open reading frame; HuLy, human lymphocyte.

(^2)
H. L. LeGros, Jr., A. Geller, and M. Kotb, manuscript in preparation.


ACKNOWLEDGEMENTS

We thank Richard Randall of the Howard Hughes Medical Institute at Duke University for performing the peptide sequence analyses and St. Jude Children's Research Hospital, Memphis, TN for allowing to use their facility to conduct the chromosomal localization study.


REFERENCES

  1. Cantoni, G. L., and Durell, J. (1957) J. Biol. Chem. 225,1033-1048 [Free Full Text]
  2. Mudd, S. H., and Cantoni, G. L. (1958) J. Biol. Chem. 231,481-492 [Free Full Text]
  3. Kotb, M., and Geller, A. M. (1993) Pharmacol. & Ther. 59,125-143
  4. Sullivan, D. M., and Hoffman, J. L. (1983) Biochemistry 22,1636-1641 [Medline] [Order article via Infotrieve]
  5. Cabrero, C., Puerta, J., and Alemany, S. (1987) Eur. J. Biochem. 170,299-304 [Abstract]
  6. Liau, M. C., Lin, G. W., and Hurlbert, R. B. (1977) Cancer Res. 37,427-435 [Abstract]
  7. Liau, M. C., Chang, C. F., Belanger, L., and Grenier, A. (1979) Cancer Res. 39,162-169 [Medline] [Order article via Infotrieve]
  8. Okada, G., Teraoka, H., and Tsukada, K. (1981) Biochemistry 20,934-940 [Medline] [Order article via Infotrieve]
  9. Abe, T., Okada, G., Teraoka, H., and Tsukada, K. (1982) J. Biochem. 91,1081-1084 [Abstract]
  10. Cabrero, C., and Alemany, S. (1988) Biochim. Biophys. Acta 952,277-281 [Medline] [Order article via Infotrieve]
  11. Suma, Y., Shimizu, K., and Tsukada, K. (1986) J. Biochem. (Tokyo) 100,67-75 [Abstract]
  12. Horikawa, S., and Tsukada, K. (1991) Biochem. Int. 25,81-90 [Medline] [Order article via Infotrieve]
  13. Alvarez, L., Corrales, F., Martin-Duce, A., and Mato, J. M. (1993) Biochem. J. 293,481-486 [Medline] [Order article via Infotrieve]
  14. Horikawa, S., Ishikawa, M., Ozasa, H., and Tsukada, K. (1989) Eur. J. Biochem. 184,497-501 [Abstract]
  15. Oden, K., and Clarke, S. (1983) Biochemistry 22,2978-2986 [Medline] [Order article via Infotrieve]
  16. Kotb, M., and Kredich, N. M. (1990) Biochim. Biophys. Acta 1039,253-260 [Medline] [Order article via Infotrieve]
  17. Geller, A. M., Kotb, M. Y., Jernigan, H. M., Jr., and Kredich, N. M. (1986) Exp. Eye Res. 43,997-1008 [Medline] [Order article via Infotrieve]
  18. Langkamp-Henken, B., Geller, A. M., LeGros, H. L., Price, J. O., De La Rosa, J., and Kotb, M. (1994) Biochim. Biophys. Acta 1201,397-404 [Medline] [Order article via Infotrieve]
  19. Kotb, M., and Kredich, N. M. (1985) J. Biol. Chem. 260,3923-3930 [Abstract]
  20. Mitsui, K., Teraoka, H., and Tsukada, K. (1988) J. Biol. Chem. 263,11211-11216 [Abstract/Free Full Text]
  21. De La Rosa, J., LeGros, H. L., Jr., Geller, A. M., and Kotb, M. (1992) J. Biol. Chem. 267,10699-10704 [Abstract/Free Full Text]
  22. De La Rosa, J., Geller, A. M., LeGros, H. L., Jr., and Kotb, M. (1992) Cancer Res. 52,3361-3366 [Abstract]
  23. Kotb, M., Geller, A. M., Markham, G. D., Kredich, N. M., De La Rosa, J., and Beachey, E. H. (1990) Biochim. Biophys. Acta 1040,137-144 [Medline] [Order article via Infotrieve]
  24. Horikawa, S., and Tsukada, K. (1992) FEBS Lett. 312,37-41 [CrossRef][Medline] [Order article via Infotrieve]
  25. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1982) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  26. Russell, D. R., and Bennett, G. N. (1982) Gene (Amst.) 20,231-243 [CrossRef][Medline] [Order article via Infotrieve]
  27. Laemmli, U. K. (1970.) Nature 227,680-685
  28. Hunkapiller, M. W., Hewick, R. M., Dreyer, W. J., and Hood, L. E. (1983) Methods Enzymol. 91,399-413 [Medline] [Order article via Infotrieve]
  29. Chirgwin, J. J., Przbyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18,5294-5299 [Medline] [Order article via Infotrieve]
  30. Maxam, A. M., and Gilbert, W. (1980) Methods Enzymol. 65,499-560 [Medline] [Order article via Infotrieve]
  31. Feinberg, A. P., and Vogelstein, B. (1983) Anal. Biochem. 132,6-13 [Medline] [Order article via Infotrieve]
  32. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74,5463-5467 [Abstract]
  33. Mead, D. A., Szczesna-Skorupa, E., and Kemper, B. (1986) Protein Eng. 1,671-674
  34. Bahnak, B. R., Howk, R., Morrissey, J. H., Ricca, G. A., Edgington, T. S., Jaye, M. C., Drohan, W. W., and Fair, D. S. (1987) Blood 69,224-230 [Abstract]
  35. Chisholm, D. (1989) BioTechniques 7,21-23 [Medline] [Order article via Infotrieve]
  36. Bradford, M. M. (1976) Anal. Biochem. 72,248-254 [CrossRef][Medline] [Order article via Infotrieve]
  37. Kozak, M. (1989) J. Cell Biol. 108,229-241 [Abstract]
  38. Arfin, S. M., and Bradshaw, R. A. (1988) Biochemistry 27,7979-7984 [Medline] [Order article via Infotrieve]
  39. Fitzgerald, M., and Shenk, T. (1981) Cell 24,251-260 [Medline] [Order article via Infotrieve]
  40. Proudfoot, N. J., and Brownlee, G. G. (1976) Nature 263,211-214 [Medline] [Order article via Infotrieve]
  41. Alvarez, L., Mingirance, J., Pajares, M. A., and Mato, J. M. (1994) Biochem. J. 261,557-561
  42. Shine, J., and Dalgarno, L. (1974) Proc. Natl. Acad. Sci. U. S. A. 71,1342-1346 [Abstract]
  43. Tabor, C. W., and Tabor, H. (1984) Adv. Enzymol. 56,251-282 [Medline] [Order article via Infotrieve]
  44. Sufrin, J. R., and Lombardini, J. B. (1980) Fed. Proc. 39,1908
  45. Oden, K. L., Carson, K., Mecham, J. O., Hoffman, R. M., and Clarke, S. (1983) Biochim. Biophys. Acta 760,270-277 [Medline] [Order article via Infotrieve]
  46. Hoffman, R. M. (1984) Biochim. Biophys. Acta 783,49-87
  47. Akerman, K., Karkola, K., and Kajander, O. (1991) Biochim. Biophys. Acta 1097,140-144 [Medline] [Order article via Infotrieve]
  48. Liau, M. C., Chang, C. F., and Becker, F. F. (1979) Cancer Res. 39,2113-2119 [Medline] [Order article via Infotrieve]
  49. Sufrin, J. R., and Lombardini, J. B. (1982) Mol. Pharmacol. 22,752-759 [Abstract]
  50. Kappler, F., Vrudhula, V. M., and Hampton, A. (1987) J. Med. Chem. 30,1599-1603 [Medline] [Order article via Infotrieve]
  51. Kappler, F., Vrudhula, V. M., and Hampton, A. (1988) J. Med. Chem. 31,384-389 [Medline] [Order article via Infotrieve]
  52. Markham, G. D., Hafner, E. W., Tabor, C. W., and Tabor, H. (1980) J. Biol. Chem. 255,9082-9092 [Abstract/Free Full Text]
  53. Peleman, J., Saito, K., Cottyn, B., Engler, G., Seurinck, J., Van Montagu, M., and Inze, D. (1989) Gene (Amst.) 84,359-369 [CrossRef][Medline] [Order article via Infotrieve]
  54. Thomas, D., and Surdin-Kerjan, Y. (1987) J. Biol. Chem. 262,16704-16709 [Abstract/Free Full Text]
  55. Thomas, D., Rothstein, R., Rosenberg, N., and Surdin, K. Y. (1988) Mol. Cell. Biol. 8,5132-5139 [Medline] [Order article via Infotrieve]
  56. Sakata, S. F., Shelly, L. L., Ruppert, S., Schutz, G., and Chou, J. Y. (1993) J. Biol. Chem. 268,13978-13986 [Abstract/Free Full Text]
  57. Horikawa, S., Sasuga, J., Shimizu, K., Ozasa, H., and Tsukada, K. (1990) J. Biol. Chem. 265,13683-13686 [Abstract/Free Full Text]
  58. Dalbøge, H., Bayne, S., and Pedersen, J. (1990) FEBS Lett. 266,1-3 [CrossRef][Medline] [Order article via Infotrieve]
  59. Hirel, P., Schmitter, J., Dessen, P., Fayat, G., and Banquet, S. (1989.) Proc. Natl. Acad. Sci. U. S. A. 86,8247-8251
  60. Lowenson, J. D., and Clarke, S. (1991) J. Biol. Chem. 266,19396-19406 [Abstract/Free Full Text]
  61. Stephenson, R. C., and Clarke, S. (1989) J. Biol. Chem. 264,6164-6170 [Abstract/Free Full Text]
  62. Cabrero, C., Duce, A. M., Ortiz, P., Alemany, S., and Mato, J. M. (1988) Hepatology 8,1530-1534 [Medline] [Order article via Infotrieve]
  63. Peterson, G. L., Rosenbaum, L. C., Broderick, D. J., and Schimerlik, M. I. (1986) Biochemistry 25,3189-3202 [Medline] [Order article via Infotrieve]
  64. Kleinschmidt, J. A., Dingwall, C., Maier, G., and Franke, W. W. (1986) EMBO J. 5,3547-3552 [Abstract]
  65. Takano, E., Maki, M., Mori, H., Hatanaka, M., Marti, T., Titani, K., Kannagi, R., Ooi, T., and Murachi, T. (1988) Biochemistry 27,1964-1972 [Medline] [Order article via Infotrieve]
  66. Kotb, M., Dale, J. B., and Beachey, E. H. (1987) J. Immunol. 139,202-206 [Abstract/Free Full Text]
  67. De La Rosa, J., Kotb, M., and Kredich, N. M. (1991) Biochim. Biophys. Acta 1077,225-232 [Medline] [Order article via Infotrieve]
  68. Geller, A. M., Kotb, M. Y., Jernigan, H. M., Jr., and Kredich, N. M. (1988) Exp. Eye Res. 47,197-204 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.